Patents by Inventor Michael L. Mitchell

Michael L. Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220298148
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 22, 2022
    Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • Publication number: 20220267343
    Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: January 18, 2022
    Publication date: August 25, 2022
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwalder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Patent number: 11352371
    Abstract: The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: June 7, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Jamie G. Bates, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Brian J. Kirby, Yurong Lai, Michael L. Mitchell, Gregg M. Schwarzwalder, James G. Taylor, Ting Wang
  • Patent number: 11151826
    Abstract: A system for limiting access to confidential information including storage circuitry for storing the confidential information. An access enabling circuit allows access to the storage circuitry in response to a first level of an enabling signal. A processor generates the enabling signal for a predetermined amount of time in response to sensing of a change of a predetermined value that is produced in response to an act by a person responsible for the confidentiality of the confidential information. The enabling signal assumes a second level after the predetermined amount of time to block access to the storage circuitry.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: October 19, 2021
    Assignee: Texas Instruments Incorporated
    Inventors: Prasanna Parthasarathy, Michael L Mitchell
  • Publication number: 20210284642
    Abstract: The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: February 23, 2021
    Publication date: September 16, 2021
    Inventors: Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
  • Patent number: 11084832
    Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: August 10, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Patent number: 10988451
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: April 27, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Publication number: 20210078991
    Abstract: Compounds disclosed herein including compounds of Formula I: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.
    Type: Application
    Filed: June 26, 2020
    Publication date: March 18, 2021
    Inventors: Zhenhong R. Cai, Hongyan Guo, Mingzhe Ji, Haolun Jin, Amy Lee, Ryan McFadden, Michael L. Mitchell, Manuel Munoz, Hyung-Jung Pyun, Lianhong Xu, Hong Yang
  • Publication number: 20210053990
    Abstract: The present disclosure relates generally to compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: August 6, 2020
    Publication date: February 25, 2021
    Inventors: Jamie G. Bates, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Brian J. Kirby, Yurong Lai, Michael L. Mitchell, Gregg M. Schwarzwalder, James G. Taylor, Ting Wang
  • Patent number: 10874640
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: December 29, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Publication number: 20200331870
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 22, 2020
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Patent number: 10800772
    Abstract: Compounds disclosed herein including compounds of Formula I: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: October 13, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Hongyan Guo, Mingzhe Ji, Haolun Jin, Amy Lee, Ryan McFadden, Michael L. Mitchell, Manuel Munoz, Hyung-Jung Pyun, Lianhong Xu, Hong Yang
  • Publication number: 20200317689
    Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: March 20, 2020
    Publication date: October 8, 2020
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Publication number: 20200273276
    Abstract: A system for limiting access to confidential information including storage circuitry for storing the confidential information. An access enabling circuit allows access to the storage circuitry in response to a first level of an enabling signal. A processor generates the enabling signal for a predetermined amount of time in response to sensing of a change of a predetermined value that is produced in response to an act by a person responsible for the confidentiality of the confidential information. The enabling signal assumes a second level after the predetermined amount of time to block access to the storage circuitry.
    Type: Application
    Filed: March 9, 2020
    Publication date: August 27, 2020
    Inventors: Prasanna Parthasarathy, Michael L Mitchell
  • Patent number: 10703733
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: July 7, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Patent number: 10586412
    Abstract: A system for limiting access to confidential information including storage circuitry for storing the confidential information. An access enabling circuit allows access to the storage circuitry in response to a first level of an enabling signal. A processor generates the enabling signal for a predetermined amount of time in response to sensing of a change of a predetermined value that is produced in response to an act by a person responsible for the confidentiality of the confidential information. The enabling signal assumes a second level after the predetermined amount of time to block access to the storage circuitry.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: March 10, 2020
    Assignee: TEXAS INSTRUMENTS INCORPORATED
    Inventors: Prasanna Parthasarathy, Michael L Mitchell
  • Publication number: 20200061024
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: May 3, 2019
    Publication date: February 27, 2020
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Publication number: 20190352271
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: May 13, 2019
    Publication date: November 21, 2019
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Patent number: 10328053
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 25, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Publication number: 20180161307
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: August 25, 2017
    Publication date: June 14, 2018
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins